Precision Age-Spot Management Serum

09/28/2026

A serum that breaks the feedback loop of a dark spot serum’s potent ingredients re-triggering the melanin they’re designed to fade. Instead, this serum acts via a single phase-separated PLGA phospholipid particle which releases the encapsulated brightener 4-butylresorcinol over 48 hours, while supporting ingredients keep skin calm. Encapsulated 4-butylresorcinol is a high-performance tyrosinase-pathway brightener delivered inside the PLGA core – composed of a lactic acid and glycolic acid copolymer – for steady exposure at a reduced surface concentration. Alongside this is tranexamic acid to support a calmer, more even tone captured in the formula’s aqueous phospholipid element; ectoin for skin comfort and resilience; ILLUMISCIN® to counteract the appearance of both melanin- and lipofuscin-related (or age-related) discoloration; and a soothing and barrier complex with bisabolol and Centella asiatica among its ingredients. In a 28-day clinical study on Asian skin, visible spot area fell over 25% with no adverse reactions.

Top 3 results, commercial formula clinical Visible age spots retreat in 28 days. 14 volunteers aged 31 to 56 with a qualifying age spot, twice daily use, single group before and after design: VISIA spot count −26.13%, spot area −25.53%, spot optical density −23.97%, all significant at p below 0.001 and already significant at Day 7. Whole face tone measurably brighter at Day 28: Melanin Index −13.36%, ITA° +25.21%, Lab lightness +4.82%, Lab redness −15.75%, all p below 0.001; dermatologist grading improved 16.37%; 100% of subjects agreed spots looked lighter. Efficacy and irritation were measured in the same subjects. 48 hour sustained delivery, an active reservoir built inside the skin. In vivo confocal Raman tracked encapsulated 4-butylresorcinol in human skin: 2.03% detected at 1 h, 11.24% at 12 h, then a stable plateau, still 11.45% at 48 h. No burst and decay: the PLGA carrier forms a stable skin reservoir. The active reached 120 μm, through the full epidermis to the basal region where melanin is produced. 55.8% of the 4-butylresorcinol is loaded inside the PLGA core. Method T/SHRH 064-2024, 2 mg per cm², one subject, six forearm sites, 15 readings each, 10 timepoints. Safety Zero adverse reactions: all 14 subjects scored grade 0 at Day 7 and Day 28 under dermatologist assessment, China Safety and Technical Standards scale. Hydroquinone free, alcohol free. Particle and platform characterization Nanoscale carriers confirmed by DLS: Z average 29.20 nm, PDI 0.3179, Dv50 18.22 nm. Platform validation at the 36th IFSCC Congress 2026, Perth, Poster ID 910: encapsulation efficiency up to 75.2%; in vitro release 97.83% cumulative at 24 h; in a separate 30 volunteer, 28 day UV induced pigmentation model, Melanin Index −14.71% and ITA° +77.56%. Statistics: two tailed tests, α 0.05; reports issued in 2026 by independent third party laboratories.

•Visibly reduces age spots: VISIA spot count −26.13% and spot area −25.53% in 28 days (n=14 clinical on the commercial formula; Asian skin, 31–56 y). •Works fast: significant spot reduction from Day 7 (count −12.83%, area −14.21%). •Brightens overall tone: ITA° +25.21%, Melanin Index −13.36%, L* +4.82% (Day 28, p<0.001). •Breaks the rebound loop—both sides measured: brightening (ITA° +25.21%) and calming (redness a* −15.75%) in the same 14 subjects, with zero adverse reactions across 28 days. •One application, 48 hours of steady delivery: in-vivo Raman shows a stable penetration plateau from 12 h through 48 h. •Dual-pigment approach: ILLUMISCIN® targets the appearance of both melanin and lipofuscin; supplier in-vivo data shows age-spot size −21.2% after 3 months (RAHN AG). •Loved in use: at Day 28, 100% of subjects agreed spots looked lighter and skin looked brighter overall; >92% rated the texture light and non-sticky. •Suitable for mature and sensitive-leaning skin; hydroquinone-free; alcohol-free; non-comedogenic

Single particle dual carrier encapsulation platform, the technology behind this serum: tri layer core shell particle—PLGA core for oil soluble actives, phospholipid bilayer for water soluble actives, polyvinyl alcohol process stabilizer—confirmed nanoscale by DLS at about 29 nm. Blended fast and slow carriers only schedule release; one phase separated particle also carries incompatible actives together. Temporal control proven in living skin: penetration climbs to a 12 hour plateau and holds through 48 hours, in vivo confocal Raman per T∕SHRH 064‑2024—one application, two days of micro dosing. In vitro corroboration: nearly 98% cumulative release at 24 hours approaching zero order kinetics; over 55% encapsulation of the product payload. Efficacy irritation decoupling by design: gradual delivery replaces burst exposure—14 of 14 subjects had zero adverse reactions over 28 days while spots faded. Scientific presentation: platform accepted at the 36th IFSCC Congress 2026, Perth, Poster ID 910. ODM solution, not a single SKU: payload agnostic, validated first on 4‑butylresorcinol, a potent unforgiving brightener, extensible to other incompatible active pairs. Opaque 30% PCR pump bottle shields light sensitive actives; oxidation protection comes from encapsulation and antioxidants.

Opaque mirror-finish bottle with a metered lotion pump: shields light-sensitive actives, dispenses a hygienic measured dose without finger contact and stays sealed between uses. Oxidation-sensitive actives are protected by the formula itself—4-butylresorcinol encapsulated in the PLGA core plus a tocopherol and metabisulfite antioxidant system—rather than by the container. Bottle incorporates 30% post-consumer recycled (PCR) plastic; recyclable bottle body. Clinical, calm design language mirroring the precision concept.

“One particle, two carriers: fading age spots without the irritation trade-off—clinically measured brightening for mature skin.” Scientific promotion: the underlying Dual-Carrier Encapsulation Platform was presented at the 36th IFSCC Congress 2026, Perth (Poster ID 910), covering coordinated delivery, controlled release, skin penetration and clinical efficacy. •Website: www.ausmetics.com—product page with technology explainer, clinical summaries, and IFSCC 2026 (Perth) poster download. •LinkedIn: Ausmetics Daily Chemicals Co., Ltd.—R&D insights, IFSCC congress updates, and B2B partnership news. •TikTok: @ausmeticsoemodm—texture and mechanism visuals (#PrecisionBrightening #OneParticleTwoCarriers). •YouTube: Ausmetics Channel—technology demos and IFSCC 2026 congress coverage.

Conventional brighteners chase one lever, melanin inhibition, and often irritate, worsening discoloration. Not an ingredient stack, not a generic release platform—one traceable chain from architecture to outcome: a 29 nm single particle dual carrier → over 55% encapsulated 4‑butylresorcinol delivered on a 48 hour in vivo plateau → spot area down over 25% in a 28 day clinical with zero adverse reactions. Plus two differentiators: a dual pigment mechanism addressing melanin and lipofuscin, the age pigment most brighteners ignore, and delivery led efficacy irritation decoupling. Precision replaces potency at any cost.

Hero ingredients •Encapsulated 4-Butylresorcinol—high-performance tyrosinase-pathway brightener delivered inside the PLGA core (Lactic Acid/Glycolic Acid Copolymer; encapsulation 55.8%) for steady exposure at reduced surface concentration. •Tranexamic Acid—4th in the INCI; supports a calmer-looking, more even tone; loaded in the aqueous phospholipid (lecithin) compartment. •Ectoin—extremolyte supporting skin comfort and resilience under environmental stress. •ILLUMISCIN® (RAHN AG)—Olea Europaea (Olive) Leaf Extract, Ascorbyl Glucoside, Zinc PCA: addresses the appearance of both melanin- and lipofuscin-related discoloration; supported by Ascorbic Acid and Diglucosyl Gallic Acid. •Soothing and barrier complex—Bisabolol, 4-t-Butylcyclohexanol, Hydroxyacetophenone, Centella Asiatica Leaf Extract, Cardiospermum Halicacabum Flower/Leaf/Vine Extract, Avena Sativa (Oat) Kernel Extract and Beta-Glucan, with microbiome and repair support from Bifida Ferment Lysate, Galactomyces Ferment Filtrate, Lactobacillus Ferment Lysate and Sodium DNA. Free-from Hydroquinone-free, alcohol (ethanol)-free, paraben-free. Full INCI list: Aqua, Butylene Glycol, Caprylic/Capric Triglyceride, Tranexamic Acid, Glycerin, Bifida Ferment Lysate, Polyglyceryl-10 Oleate, Galactomyces Ferment Filtrate, Octyldodecanol, Dimethicone, Pentylene Glycol, 1,2-Hexanediol, Hydroxyacetophenone, Sodium Polyacryloyldimethyl Taurate, Ammonium Acryloyldimethyltaurate/VP Copolymer, Lactobacillus Ferment Lysate, Tocopheryl Acetate, Citric Acid, Hydrogenated Polydecene, Sodium Stearoyl Glutamate, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Maltodextrin, Tocopherol, Olea Europaea (Olive) Leaf Extract, Ascorbyl Glucoside, Zinc PCA, Ascorbic Acid, Lactic Acid/Glycolic Acid Copolymer, 4-Butylresorcinol, Lecithin, Ectoin, Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate, Bisabolol, Diglucosyl Gallic Acid, Echium Plantagineum Seed Oil, Citrus Tangerina (Tangerine) Peel Oil, Sodium Metabisulfite, Gentiana Scabra Root Extract, Disodium EDTA, 4-t-Butylcyclohexanol, Dimethiconol, Helianthus Annuus (Sunflower) Seed Oil Unsaponifiables, Sodium DNA, Trideceth-10, Pyracantha Fortuneana Fruit Extract, Avena Sativa (Oat) Kernel Extract, Tasmannia Lanceolata Leaf Extract, Cardiospermum Halicacabum Flower/Leaf/Vine Extract, Centella Asiatica Leaf Extract, Sodium Hyaluronate, Zingiber Officinale (Ginger) Root Extract, Caprylhydroxamic Acid, Beta-Glucan, Caprylyl Glycol.

•Morning and evening, after cleansing, dispense 1–2 pumps; massage gently until absorbed. •A second thin layer may be focused on visible spot areas. •In daytime always pair with broad-spectrum sunscreen—UV exposure drives age-spot formation. •Use daily and continuously: clinical improvements were measured at 7 and 28 days of twice-daily use. Suitable for mature and sensitive-leaning skin; patch-test first if highly reactive.

• Manufacturing: ISO 22716 (Cosmetic GMP) certified facility; GMPC certified. • Ethics: Sedex member; SMETA third-party social audits covering labor, health & safety, environment and business ethics. • Registration: U.S. FDA cosmetic establishment registration. • Formulation: biodegradable PLGA carrier; cruelty-free—no animal testing of the finished product. • Packaging: pump bottle with 30% PCR content; recyclable bottle body. • Ingredient level: selected components carry ECOCERT/COSMOS approvals.

•Patent (granted): Chinese invention patent ZL 2024 1 1196592.9 (grant publication CN 119033659 B; certificate No. 8047054), “A brightening composition suitable for sensitive skin, its use and cosmetic” •Evidence on file: human efficacy report SHA01-26040255-JC-01 (Guangdong Weipu, issued 25 May 2026); in-vivo Raman penetration report SGXY-20260423JYF02 (per T/SHRH 064-2024); DLS particle-size report SHA01-26051759-FX-01 (Shanghai Weipu, 1 June 2026). •Scientific validation: accepted for the 36th IFSCC Congress 2026, Perth, Australia (Poster ID 910). •Quality: manufactured under ISO 22716 cosmetic GMP; batch-specific Certificates of Analysis are maintained. Formula stability and packaging compatibility were evaluated under internal protocols, with no material changes affecting product quality or package integrity observed over the completed test period. Supporting records are maintained on file. •Safety: zero adverse reactions in the 28-day dermatologist-assessed use test (14/14 subjects, grade 0). •Corporate: Sedex/SMETA audited; U.S. FDA registered.